-20℃ 3 years powder
-80℃ 2 years in solvent
Centrinone (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | inquiry | 98.00 | |
5 mg | inquiry | 146.00 | |
10 mg | inquiry | 239.00 | |
50 mg | inquiry | 971.00 | |
100 mg | inquiry | 1763.00 | |
200 mg | inquiry | inquiry | |
500 mg | inquiry | inquiry | |
1 mL * 10 mM (in DMSO) | inquiry | 202.00 |
Description | Centrinone (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM). |
Targets&IC50 | PLK4 :ic50 0.16 nM (ki), PLK4 G95L :ic50 68.57 nM (ki), Aurora A :ic50 171 nM (ki), Aurora B :ic50 436.76 nM (ki), |
In vitro | Centrinone treatment causes centrosome depletion in human and other vertebrate cells and reduces centriole number in multiciliated Xenopus epithelial cells. Centrinone treatment of HeLa human cervical carcinoma cells leads to a progressive reduction in foci containing centriolar and pericentriolar material markers at each round of cell division until most cells lack centrioles and centrosomes. Centrosome loss irreversibly arrests normal cells in a senescence-like G1 state by a p53-dependent mechanism that is independent of DNA damage, stress, Hippo signaling, extends mitotic duration, or segregation errors. |
Synonyms | LCR-263 |
Purity | 98.00% |
Molecular Weight | 633.65 |
Formula | C26H25F2N7O6S2 |
CAS No. | 1798871-30-3 |
-20℃ 3 years powder
-80℃ 2 years in solvent
DMSO: 31 mg/mL (48.92 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
Safe and effective drug dosing is necessary, regardless of its purpose of administration. Learn More
bottom
Answers to questions you may have can be found in the Inhibitor Handling Instructions. Topics include how to prepare stock solutions, how to store Products, and issues that need special attention for cell-based assays and animal experiments.